BETHESDA, Md. – Rockridge Venture Law® patent attorney Kevin Christopher and patent agent Andrew Lerner have been appointed as faculty members to the newly launched NIH Rapid Acceleration of Diagnostics (RADx) program. RADx is a fast-track technology development program that leverages the NIH Point-of-Care Technology Research Network (POCTRN). RADx will support novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches. RADx is structured to deliver innovative testing strategies to the public as soon as late summer 2020 and is an accelerated and comprehensive multi-pronged effort by NIH to make SARS-CoV-2 testing readily available to every American. Learn more about RADx at https://www.poctrn.org/radx.
